It is well known that BRCA1 and BRCA2 play a central role in DNA repair, but the relationship between BRCA1 and BRCA2 mRNA expression and response to neoadjuvant chemotherapy in sporadic breast cancer patients has not been well established. Here, we investigate the association between BRCA1 or BRCA2 mRNA expression levels and pathological response in 674 BRCA1/2 mutationnegative breast cancer patients who received neoadjuvant chemotherapy. BRCA1 and BRCA2 mRNA expression were assessed using quantitative real-time polymerase chain reaction in core biopsy breast cancer tissue obtained prior to the initiation of neoadjuvant chemotherapy. A total 129 patients (19.1%) achieved pathological complete response (pCR) after neoadjuvant chemotherapy. Among patients treated with anthracycline-based chemotherapy (n = 531), BRCA1 mRNA low expression patients had a significantly higher pCR rate than intermediate or high BRCA1 mRNA expression groups (24.6% vs 16.8% or 14.0%, P = .031) and retained borderline significance (OR = 1.54, 95% CI = 0.93-2.56, P = .094) in multivariate analysis. Among the 129 patients who received a taxane-based regimen, pCR rate showed no differences in BRCA1 low, intermediate, and high mRNA level subgroups (19.6%, 26.8% and 21.4%, respectively; P = .71). BRCA2 mRNA level was not associated with pCR rate in the anthracyline-based treated subgroup (P = .60) or the taxane-based regimen subgroup (P = .82). Taken together, our findings suggested that BRCA1 mRNA expression could be used as a predictive marker in BRCA1/2 mutation-negative breast cancer patients who received neoadjuvant anthracycline-based treatment. -
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| INTRODUCTION
BRCA1 and BRCA2 genes play important roles in DNA repair, cell cycle checkpoint control, transcriptional regulation, and ubiquitination. [1] [2] [3] Thus, deficiencies in these genes can impact the response of cancer cells to chemotherapy drugs. Several studies have demonstrated that BRCA1 or BRCA2 germline mutation carriers were more sensitive than non-carriers to chemotherapy drugs. [4] [5] [6] [7] [8] [9] However, BRCA1/2 germline mutations are rarely observed in sporadic breast cancer, comprising only approximately 2% of breast cancers overall 10, 11 and approximately 1.1% of breast cancer cases in China. 12 In addition to BRCA1/2 germline mutations, other BRCA defects, including methylation of the BRCA1 promoter, low expression, and copy number deletions in some sporadic cancers share similar phenotypic characteristics with tumors that carry BRCA1/2 mutations. 13 Decreased BRCA1 mRNA expression in breast cancer cell lines increased sensitivity to etoposide and cisplatin, 14, 15 whereas overexpression of BRCA1 in murine ovarian cancer cells increased resistance to cisplatin, etoposide, and doxorubicin. 16, 17 Consistent with these in vitro findings, we previously demonstrated that methylation of the BRCA1 promoter is significantly associated with sensitivity to adjuvant chemotherapy in triple-negative breast cancer patients and with good outcome. 18 However, several studies also showed that inhibition of BRCA1 expression resulted in resistance to paclitaxel and vincristine. 14, 19 Moreover, relatively few studies to date have reported the relationship of BRCA2 mRNA expression and response to chemotherapy in breast cancers. Thus, the role of BRCA1 and BRCA2 as predictors of differential response to neoadjuvant chemotherapy in breast cancer has not been well established. In particular, few studies have excluded the effect of BRCA1/2 germline mutations to determine whether BRCA1 or BRCA2 mRNA expression levels contribute to response to chemotherapy agents.
To address these problems, we measured mRNA expression levels of BRCA1 and BRCA2 in a cohort of 674 Chinese breast cancer patients without BRCA1/2 germline mutations who received neoadjuvant chemotherapy. We also evaluated the effect of BRCA1
and BRCA2 mRNA expression levels on the prediction of various neoadjuvant chemotherapy regimens. 
| MATERIALS AND METHODS

| Patients
| Neoadjuvant chemotherapy regimens
Among the total 674 BRCA1/2 mutation-negative patients, 94%
received four to eight cycles of neoadjuvant chemotherapy. Treatments were categorized into three subgroups.
1.
A total of 531 patients received an anthracycline-based regimen. 
3.
The remaining 14 patients received other regimens.
After completion of neoadjuvant chemotherapy, patients were treated with mastectomy (n = 398) or breast-conserving surgery (n = 276) depending on tumor size, presence of multiple lesions or patient preference. pCR was defined as no invasive breast cancer cells in the breast after completion of neoadjuvant chemotherapy. Results obtained were the mean of three independent experiments.
| BRCA1 and BRCA2 germline mutation analysis by sequencing
Genomic DNA was isolated from peripheral mononuclear blood cells using the phenol-chloroform assay. BRCA1 and BRCA2 genes were screened by PCR sequencing assay as described elsewhere. 23 We screened the entire coding regions and exon-intron boundaries of BRCA1 and BRCA2 for all 701 breast cancer patients. Table 1 shows the clinicopathological characteristics for all patients (n = 674). Patients with low BRCA1 mRNA level were more likely to have ER-negative (P = .002), PR-negative (P = .006), and HER2-positive expression (P = .025), whereas patients with low BRCA2 mRNA level were more likely to be ER-positive (P = .032), PR-positive (P = .01), HER2-negative (P = .011), and lymph node positive (P = .027). Patients with low BRCA1 mRNA expression level were also more likely to be triple-negative (P = .014). Neither BRCA1 nor BRCA2 mRNA expression was significantly associated with age at diagnosis or tumor size ( respectively; P = .82). Additional factors associated with pCR included tumor size (P = .003), lymph node status (P < .001), tumor grade (P < .001), ER status (P < .001), PR status (P < .001), and HER2 status (P = .01) ( Table 2 ).
Patients were also divided into three treatment subgroups according to treatment regimen. No significant differences in BRCA1
and BRCA2 mRNA expression were found among the anthracyclinebased treatment group, taxane-treated group, and other regimen groups (P = .92 and P = .35, respectively) ( Table 1) . pCR rates were also not significantly different in the three treatment groups (18.5% vs 22.5% vs 14.3%, P = .52) ( Table 2) .
Among the patients who received anthracycline with or without taxane-based neoadjuvant chemotherapy regimen (n = 531), patients with low BRCA1 mRNA expression had significantly higher pCR rate BCS, breast-conserving surgery; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; pCR, pathological complete response; PR, progesterone receptor.
T Figure 2B ).
| DISCUSSION
In the present study, we investigated the association between BRCA1 and BRCA2 mRNA levels and response to neoadjuvant chemotherapy in 674 Chinese breast cancer patients without BRCA1/2 germline mutations. We found that patients with low expression of BRCA1 mRNA were more likely to respond to anthracycline-based neoadjuvant chemotherapy than patients with intermediate or high BRCA1 mRNA levels. Previous studies reported the association between BRCA1 and BRCA2 expression and response to chemotherapy; however, the results shown were less consistent. [26] [27] [28] Some clinical data suggested that tumors with low BRCA1 or BRCA2 mRNA expression responded better to DNA-damaging chemotherapy, 27-29 whereas some showed no relationship between BRCA1 or BRCA2 expression and chemotherapy sensitivity. 28, 30 However, the sample size of previous studies was relatively small. Moreover, the previous studies did not take the BRCA1/2 germline mutations into consideration when investigating the relationship between mRNA expression level of BRCA1/2 and response to neoadjuvant chemotherapy, as BRCA1 germline mutations may affect the response to some chemotherapy drugs. 31 One advantage of the current study was that the germline mutations of BRCA1 and BRCA2 genes in this cohort had been analyzed through sequencing assay, and BRCA1/2 gene germline mutations status was clearly shown in our previous reports. 24, 25 To the best of our knowledge, this is the first study to report that BRCA1 and BRCA2 mRNA expression level was associated with response to neoadjuvant chemotherapy in a relatively large sample size, excluding the effects of BRCA1 and BRCA2 gene mutations. The present study had several limitations. Neoadjuvant chemotherapy regimens were not assigned randomly, and a small number of patients received taxane-based neoadjuvant chemotherapy.
In summary, our study suggests that in the absence of BRCA1/2 germline mutations, breast cancer patients with low BRCA1 mRNA expression have a higher pCR rate to anthracycline-based neoadju- 
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